ARS Pharmaceuticals, Inc.
NGM: SPRYLive Quote
📈 ZcoreAI Score
Our AI model analyzes ARS Pharmaceuticals, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get SPRY Z-Score →About ARS Pharmaceuticals, Inc.
Healthcare
Biotechnology
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
📊 Fundamental Analysis
ARS Pharmaceuticals, Inc. demonstrates a profit margin of -203.3%, which is below the sector average, suggesting competitive pressure.
The company recently reported -67.6% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -92.3%, which indicates that capital utilization is currently under pressure.
At a current price of $8.05, SPRY currently trades near the bottom of its 52-week range (11%), indicating potential value or weakness (Range: $6.66 - $18.90).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$799.34M
Trailing P/E
--
Forward P/E
-11.14
Beta (5Y)
0.93
52W High
$18.90
52W Low
$6.66
Avg Volume
1.35M
Day High
Day Low